U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NTP Logo

Annual Report for Fiscal Year 2018

Annual Report for Fiscal Year 2018

Toxicogenomic Studies

NTP is incorporating the latest toxicogenomic technologies into its testing program to gain further insights into the toxicity of environmental substances. Toxicogenomics examines how the entire genetic structure, or genome, influences an organism’s response to environmental toxicants. Microarray, proteomic, metabolomics analyses, and next-generation (NextGen) sequencing are among the advanced technologies that NTP is using to study how chemical exposures change the expression of genes, proteins, and metabolites in targeted cells and tissues.

Measuring genome-wide changes in affected tissues could be useful for identifying disease biomarkers, detecting exposure to toxic substances, and understanding individual genetic susceptibilities. Once validated, biomarkers can be repeatedly sampled during long-term NTP studies to determine if chemical exposures can be detected or if developing diseases (e.g., cancer) provide a genetic signature.

NTP is investigating whether pattern analysis of gene expression can provide toxicity indicators at (1) earlier time points and (2) lower doses than are possible using traditional toxicological parameters. Evaluating patterns of gene expression is expected to provide insight into the pathogenesis of disease and how different rodent models respond to toxicants. In addition, metabolomics provides an opportunity to elucidate how chemicals affect metabolism within cells relative to changes in gene expression. Expression signatures linked to chemical exposures and apical measures are intended to contribute to NTP’s efforts in predictive toxicology.

Several FY 2018 toxicogenomic studies used NextGen sequencing technologies, which improves gene expression analysis, including base pair-level resolution of accuracy and increased sensitivity compared to microarray platforms. Although microarray analysis is a stable and well-understood technology for assaying gene expression, NextGen sequencing methods like RNA-seq likely will become more common as sequencing costs decline and bioinformatic analyses become standardized and integrated with genomic sequencing.

One promising research area is the application of exome sequencing (Exome-Seq) to either frozen or formalin-fixed, paraffin-embedded tissues. DNA can be extracted from either frozen or archival tissues. Coding portions of DNA, or exons, are captured by libraries of hybridization-based probes targeting over 200,000 exons and transcriptionally active regions. Exon-enriched DNA can be sequenced by DNA-Seq and then genomically aligned to find mutation insertions or deletions and other genetic abnormalities associated with disease. An additional area of development is the isolation of circulating, cell-free DNA (ccfDNA). DNA released from apoptosis or cell turnover normally appears in plasma, but chemical exposure can increase levels of ccfDNA due to toxicity, inflammation, or tumor development. The NTP is investigating the use and sequencing of ccfDNA in toxicology studies to determine its use as a new marker of chemical exposure.

Several NTP studies are using Exome-Seq for profiling mutations on a genome-wide scale to understand differences between spontaneous and chemically induced tumors. Another promising NextGen sequencing-related area in toxicogenomics is the S1500+ platform. This platform provides a way to use high-throughput transcriptomic screening for thousands of genes per sample and can be applied to both in vitro chemical toxicity screening and in vivo screening of RNA extracted from animal tissues.

NTP is evaluating study conditions that could contribute to differential gene expression, such as animal and tissue variability, methods for tissue sampling, and standards for conducting toxicogenomic studies under laboratory conditions. Efforts are underway to optimize methods for DNA and RNA extraction from archival tissues for molecular analysis. Planned or ongoing NTP toxicogenomic studies from FY 2018 are listed below.

Toxicogenomic Studies Planned or Ongoing in FY 2018

Chemical (CASRN*) Species/ Cell Line Route Duration Test Type (Platform) Study Scientist
Arsenite (7784-46-5) Human prostate cell line In vitro 30 weeks NextGen sequencing Exome-Seq (Illumina) Alex Merrick
2,3-Butanedione (diacetyl) (431-03-8)

2,3-Hexanedione (3848-24-6)
Human airway epithelium cell line In vitro 4 days High-throughput transcriptomic screening William Gwinn
Bisphenol A and analogues (80-05-7) Human hepatocyte cell line In vitro 2 days High-throughput transcriptomic screening Mike DeVito
Bisphenol AF (1478-61-1)

Tetrabromobisphenol A (79-94-7)
Rat Gavage 5 days S1500+ NextGen sequencing Sue Fenton
Bromodichloroacetic acid (5589-96-8)

Methyleugenol (93-15-2)
Mouse Gavage 2 years NextGen sequencing Exome-Seq (Illumina) Arun Pandiri
Dieldrin (60-57-1)

Ethinyl estradiol (57-63-6)

Methyl mercury (115-09-3)

Rotenone (83-79-4)

Phenol (68937-41-7)

Isopropylated phosphate (3:1) (60348-60-9)

Pentabromodiphenyl ether (60348-60-9)
Mouse In vitro 1 day S1500+, NextGen sequencing Alison Harrill
Phosphate flame retardants:

tert-Butylphenyl diphenyl phosphate (56803-37-3)

2-Ethylhexyl diphenyl phosphate (1241-94-7)

Isodecyl diphenyl phosphate (29761-21-5)

Isopropylated phenol phosphate (68937-41-7)
Rat Gavage 5 days Microarray (Affymetrix) Metabolomics Scott Auerbach
Ginkgo biloba extract (90045-36-6) Rat Gavage 5 days Microarray (Affymetrix) Cynthia Rider, Scott Auerbach
Induced pluripotent stem cells Embryoid bodies Embryonic stem cells Human stem cell N/A N/A High-throughput transcriptomic screening Erik Tokar, Mike DeVito
PCB-11 (2050-67-1) Rat

Human hepatocyte cell line
In vitro 1 day S1500+ NextGen sequencing Mike DeVito
PBDE-47 (32534-81-9) Rat Gavage 21 days Microarray June Dunnick
Polycyclic aromatic compounds:

Acenaphthenequinone (82-86-0)

Benzo[b]fluoranthene (205-99-2)

Benzo(a)pyrene (50-32-8)

Dibenz[a,h]anthracene (53-70-3)

9-Methylanthracene (779-02-2)

1-Methylfluorene (1730-37-6)

Perinaphthenone (548-39-0)

Phenanthrene (85-01-8)

Pyrene (129-00-0)
Human hepatocyte cell line In vitro 2 days Cytotoxicity and gene expression by quantitative polymerase chain reaction Cynthia Rider, Erik Tokar
Tetrabromobisphenol A (79-94-7)

Pentabromodiphenyl oxide-technical (DE-71) (32534-81-9)

Triclosan (3380-34-5)

alpha, beta-Thujone (76231-76-0)
Rat Gavage 5 days High-throughput transcriptomic screening Mike DeVito, William Gwinn
112-chemical compound test set (pharmaceuticals and environmental compounds) Human hepatocyte cell line-HepaRG In vitro 2 days High-throughput transcriptomic screening Stephen Ferguson, Sreenivasa Ramaiahgari
20-chemical compound test set (environmental compounds) Primary rat hepatocytes Human HepaRG cells In vitro 3 days S1500+ NextGen sequencing William Gwinn, Mike DeVito
N/A Human mRNA Reference Isolation In vitro N/A S1500+ NexGen Sequencing Richard Paules
Carcinogens (HCC100) Mouse In vivo 2 years HCC RNA-seq, CNV array Miaofei Xu,
Arun Pandiri

*Chemical Abstracts Service Registry Number
**This study will compare toxicogenomic effects among the chemicals listed together.

Related Links:
Disposition, Metabolism, and Toxicokinetic Studies
Genetic Toxicity Studies
Organ System Toxicity Studies
Modified One-Generation Reproduction Studies
Toxicology and Carcinogenicity Studies